Summary: In an effort to find new repurposed antibacterial compounds, we performed the screening of an FDA-approved compounds library against Staphylococcus aureus. Compounds were evaluated for their activity agasint both planktonic cells and biofilms. One of the identified hits was fingolimod, an immunomodulator approved for the treatment of multiple sclerosis, and it was selected for follow-up studies. Fingolimod displayed a potent bactericidal activity against S. aureus, S. epidermidis and Acinetobacter baumannii. No resistance was developed against fingolimod for up to 20 days and it inhibits quorum sensing in Chromobacterium violaceum and might therefore target this signaling pathway in other Gram-negative bacteria.
Read the original article, published in Microorganisms here.